Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

47
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

102
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
102
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

44
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

57
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

39
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

198
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
198

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety evaluation of the food enzyme triacylglycerol lipase from the genetically modified <i>Trichoderma reesei</i> strain DP-Nzk118.

EFSA journal. European Food Safety Authority·2026
Same author

Critical-Priority Enterobacterales in Samples from Procellariiform Seabirds: Detection of NDM-1 and CTX-M-8 Co-Producing APEC-Associated E. coli.

Journal of applied microbiology·2026
Same author

Safety evaluation of the food enzyme thermolysin from the non-genetically modified <i>Anoxybacillus caldiproteolyticus</i> strain DP-Fzj32.

EFSA journal. European Food Safety Authority·2026
Same author

Joint Attention in Late Preterm Infants: Developmental Trajectory and Contribution of Maternal Interaction.

Infancy : the official journal of the International Society on Infant Studies·2026
Same author

Safety evaluation of the food enzyme β-glucosidase from the genetically modified <i>Trichoderma reesei</i> strain DP-Nyk114.

EFSA journal. European Food Safety Authority·2026
Same author

N170 and N250 in schizophrenia spectrum disorder: systematic review and meta-analysis.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2026

Related Experiment Video

Updated: Oct 26, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.6K

Nephrotoxicity in Neonates.

Henrique Soares1,2, Rita Moita1,2, Pedro Maneira1

  • 1Neonatal Intensive Care Unit, Neonatology Department.

Neoreviews
|August 3, 2021
PubMed
Summary
This summary is machine-generated.

Acute kidney injury (AKI) in newborns is often overlooked and can result from nephrotoxic medications. Prevention and management strategies are crucial for long-term infant health.

More Related Videos

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
07:58

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury

Published on: July 17, 2016

9.0K
Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

59.9K

Related Experiment Videos

Last Updated: Oct 26, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

6.6K
Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
07:58

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury

Published on: July 17, 2016

9.0K
Intravenous Injections in Neonatal Mice
05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

59.9K

Area of Science:

  • Neonatology
  • Pediatric Nephrology
  • Pharmacology

Background:

  • Acute kidney injury (AKI) in neonates is a significant clinical challenge, often underrecognized with unknown incidence.
  • Nephrotoxic medications, frequently administered to critically ill neonates, pose a substantial risk for renal injury and impaired nephrogenesis, especially in preterm infants.
  • Limited data exist on the pharmacokinetics and pharmacodynamics of medications in neonates, leading to frequent off-label use.

Purpose of the Study:

  • To review the key aspects of nephrotoxicity in neonates.
  • To outline current strategies for the prevention and treatment of AKI in this vulnerable population.
  • To emphasize the importance of long-term follow-up for neonates experiencing AKI.

Main Methods:

  • This review synthesizes existing literature on neonatal AKI and nephrotoxicity.
  • It examines causes, risk factors, and clinical implications of AKI in newborns.
  • The review discusses preventative measures, therapeutic interventions, and long-term care.

Main Results:

  • AKI in neonates can stem from prerenal, intrinsic, or postrenal causes, with medication toxicity being a major concern.
  • Preventative strategies focus on maintaining hemodynamic stability, adequate oxygenation, and judicious use of nephrotoxic drugs.
  • Treatment involves fluid and electrolyte balance, nutritional support, and vigilant monitoring.

Conclusions:

  • Neonates are particularly susceptible to the acute and long-term consequences of AKI.
  • Proactive prevention, timely treatment, and consistent follow-up are essential for improving outcomes in neonatal AKI.
  • Further research into neonatal pharmacokinetics and pharmacodynamics is needed to optimize medication safety.